Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target
Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
Stocks · News reference
Crescent Biopharma Commences Offering Of Common Stock, Pre-Funded Warrants; Terms Undisclosed
Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma reported Q2 2026 results with continued enrollment in its ASCEND Phase 1/2 trial for CR-001, a PD-1 x VEGF bispecific antibody. The company completed a $143.7 million public offering extending cash runway to H2 2028 and announced multiple clinical data readouts expected beginning Q1 2027. R&D expenses increased to $19.4 million due to expanded clinical activities, while the company maintains strategic partnerships with Kelun-Biotech for development in Greater China.
Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
8-K filing — CRESCENT BIOPHARMA, INC. (CBIO)
Filed: 2026-07-30 AccNo: 0001628280-26-050805 Size: 321 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits